Noboru Nakaigawa

Novel mutations of the MET proto-oncogene in papillary renal carcinomas

Laura S. Schmidt, Kerstin Junker, Noboru Nakaigawa et al. · Oncogene · 1999 · 504 citations

Papillary Renal Carcinomas, Tumor Biology, Tumor Heterogeneity +8

Activating mutations for the Met tyrosine kinase receptor in human cancer

Michael Jeffers, Laura S. Schmidt, Noboru Nakaigawa et al. · Proceedings of the National Academy of Sciences · 1997 · 440 citations

Tumor Biology, Radiation Oncology, Signal Transduction +14

Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development

Hitoshi Ishiguro, Noboru Nakaigawa, Yasuhide Miyoshi et al. · The Prostate · 2005 · 212 citations · Full text

Comprehensive mutational analysis of the <i>VHL</i> gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters

Keiichi Kondo, Masahiro Yao, Minoru Yoshida et al. · Genes Chromosomes and Cancer · 2002 · 194 citations

Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor.

Hiroji Uemura, Hitoshi Ishiguro, Noboru Nakaigawa et al. · PubMed · 2003 · 187 citations

Prostate Cancer Cells, Pharmacotherapy, Tumor Biology +17